Milbank LLP advised invoX Pharma Limited (“invoX”), a UK-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), in connection with the CFIUS clearance for its $161 million acquisition of F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy.
invoX focuses on R&D and business development activities with its primary focus on oncology and respiratory therapeutics. Sino Biopharm is a global top 50 pharmaceutical company with more than 24,000 employees.
The Milbank team was led by Washington DC-based CFIUS partner John Beahn and special counsel Dana Zelman with support from Transportation and Space partner Dara Panahy and Global Risk & National Security associate Ethan Heben.
